Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash to Debt 2.86
NSPR's Cash to Debt is ranked higher than
53% of the 326 Companies
in the Global Medical Devices industry.

( Industry Median: 2.32 vs. NSPR: 2.86 )
Ranked among companies with meaningful Cash to Debt only.
NSPR' s Cash to Debt Range Over the Past 10 Years
Min: 0.23  Med: 6.63 Max: No Debt
Current: 2.86
Equity to Asset 0.50
NSPR's Equity to Asset is ranked lower than
68% of the 304 Companies
in the Global Medical Devices industry.

( Industry Median: 0.63 vs. NSPR: 0.50 )
Ranked among companies with meaningful Equity to Asset only.
NSPR' s Equity to Asset Range Over the Past 10 Years
Min: -1.69  Med: 0.18 Max: 0.78
Current: 0.5
-1.69
0.78
F-Score: 4
Z-Score: -15.74
M-Score: 0.76
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -410.34
NSPR's Operating margin (%) is ranked lower than
88% of the 308 Companies
in the Global Medical Devices industry.

( Industry Median: 2.42 vs. NSPR: -410.34 )
Ranked among companies with meaningful Operating margin (%) only.
NSPR' s Operating margin (%) Range Over the Past 10 Years
Min: -840.95  Med: -328.01 Max: -228.66
Current: -410.34
-840.95
-228.66
Net-margin (%) -452.59
NSPR's Net-margin (%) is ranked lower than
88% of the 308 Companies
in the Global Medical Devices industry.

( Industry Median: 1.87 vs. NSPR: -452.59 )
Ranked among companies with meaningful Net-margin (%) only.
NSPR' s Net-margin (%) Range Over the Past 10 Years
Min: -890.53  Med: -600.41 Max: -244.25
Current: -452.59
-890.53
-244.25
ROA (%) -134.33
NSPR's ROA (%) is ranked lower than
92% of the 330 Companies
in the Global Medical Devices industry.

( Industry Median: 0.20 vs. NSPR: -134.33 )
Ranked among companies with meaningful ROA (%) only.
NSPR' s ROA (%) Range Over the Past 10 Years
Min: -436.36  Med: -280.11 Max: -80
Current: -134.33
-436.36
-80
ROC (Joel Greenblatt) (%) -1956.66
NSPR's ROC (Joel Greenblatt) (%) is ranked lower than
89% of the 325 Companies
in the Global Medical Devices industry.

( Industry Median: 3.44 vs. NSPR: -1956.66 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NSPR' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -8439.86  Med: -2659.05 Max: -1484.91
Current: -1956.66
-8439.86
-1484.91
Revenue Growth (3Y)(%) -53.00
NSPR's Revenue Growth (3Y)(%) is ranked lower than
94% of the 233 Companies
in the Global Medical Devices industry.

( Industry Median: 3.90 vs. NSPR: -53.00 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
NSPR' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -26.5 Max: -41.4
Current: -53
EBITDA Growth (3Y)(%) -40.40
NSPR's EBITDA Growth (3Y)(%) is ranked lower than
94% of the 195 Companies
in the Global Medical Devices industry.

( Industry Median: 4.00 vs. NSPR: -40.40 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
NSPR' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -40.4  Med: 236.25 Max: 685.3
Current: -40.4
-40.4
685.3
EPS Growth (3Y)(%) -40.10
NSPR's EPS Growth (3Y)(%) is ranked lower than
90% of the 196 Companies
in the Global Medical Devices industry.

( Industry Median: 2.70 vs. NSPR: -40.10 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
NSPR' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -40.1  Med: 210.5 Max: 698.9
Current: -40.1
-40.1
698.9
» NSPR's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

NSPR Guru Trades in

NSPR Guru Trades in

NSPR Guru Trades in

Q3 2016

NSPR Guru Trades in Q3 2016

Jim Simons 1,923,051 sh (New)
» More
» Details

Insider Trades

Latest Guru Trades with NSPR

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Devices » Medical Devices    NAICS: 339112    SIC: 3841
Compare:OTCPK:PETV, OTCPK:VYCO, OTCPK:ACAR, NAS:SSH, OTCPK:EQUR, OTCPK:AIRW, NAS:MDGS, OTCPK:VRSEF, AMEX:XTNT, OTCPK:ECGI, OTCPK:IGNG, OTCPK:ESMC, NAS:DYNT, OTCPK:MRIC, OTCPK:BIAD, OTCPK:TMEDD, OTCPK:SMLR, NAS:AHPI, OTCPK:PBIO, NAS:ETRM » details
Traded in other countries:II2N.Germany,
InspireMD Inc together with its subsidiaries, is a medical device company focusing on the development and commercialization of its proprietary stent platform technology, MGuard.

InspireMD Inc was organized in the State of Delaware on February 29, 2008 as Saguaro Resources, Inc. On March 28, 2011, it effectuated a 1-for-3 forward stock split and changed its name from Saguaro Resources, Inc. to InspireMD, Inc. It is an medical device company focusing on the development and commercialization of its proprietary stent platform technology, MGuard. MGuard provides embolic protection in stenting procedures by placing a micron mesh sleeve over a stent. The Company's initial products are marketed for use mainly in patients with acute coronary syndromes, notably acute myocardial infarction (heart attack) and saphenous vein graft coronary interventions (bypass surgery). According to the TYPHOON STEMI trial and the SOS SVG Trial of patients with acute myocardial infarction and saphenous vein graft coronary interventions, 7.5% to 44% experience adverse cardiac events, including cardiac death, heart attack, and restenting of the artery. When performing stenting procedures in patients with acute coronary symptoms, interventional cardiologists face a difficult dilemma in choosing between bare-metal stents, which have a high rate of restenosis (formation of new blockages), and drug-eluting (drug-coated) stents, which have a high rate of late thrombosis (formation of clots months or years after implantation), require administration of anti-platelet drugs for at least one year post procedure, are more costly than bare-metal stents and have additional side effects. It intends to use its MGuard technology in a broad range of coronary related situations in which complex lesions are required and make it an industry standard for treatment of acute coronary syndromes. It also intends to apply its technology to develop additional products used for other vascular procedures, specifically carotid (the arteries that supply blood to the brain) and peripheral (other arteries) procedures. The Company markets its products through distributers in international markets, mainly in Europe and Latin America.

Ratios

vs
industry
vs
history
P/B 0.67
NSPR's P/B is ranked higher than
95% of the 300 Companies
in the Global Medical Devices industry.

( Industry Median: 3.08 vs. NSPR: 0.67 )
Ranked among companies with meaningful P/B only.
NSPR' s P/B Range Over the Past 10 Years
Min: 0.32  Med: 12.34 Max: 360.33
Current: 0.67
0.32
360.33
P/S 0.61
NSPR's P/S is ranked higher than
91% of the 294 Companies
in the Global Medical Devices industry.

( Industry Median: 3.02 vs. NSPR: 0.61 )
Ranked among companies with meaningful P/S only.
NSPR' s P/S Range Over the Past 10 Years
Min: 0.3  Med: 10.45 Max: 98.75
Current: 0.61
0.3
98.75
EV-to-EBIT 0.30
NSPR's EV-to-EBIT is ranked higher than
99% of the 169 Companies
in the Global Medical Devices industry.

( Industry Median: 21.46 vs. NSPR: 0.30 )
Ranked among companies with meaningful EV-to-EBIT only.
NSPR' s EV-to-EBIT Range Over the Past 10 Years
Min: -49.4  Med: -2.95 Max: 0.4
Current: 0.3
-49.4
0.4
EV-to-EBITDA 0.30
NSPR's EV-to-EBITDA is ranked higher than
99% of the 182 Companies
in the Global Medical Devices industry.

( Industry Median: 16.23 vs. NSPR: 0.30 )
Ranked among companies with meaningful EV-to-EBITDA only.
NSPR' s EV-to-EBITDA Range Over the Past 10 Years
Min: -50  Med: -3 Max: 0.4
Current: 0.3
-50
0.4
Current Ratio 2.07
NSPR's Current Ratio is ranked lower than
60% of the 327 Companies
in the Global Medical Devices industry.

( Industry Median: 2.43 vs. NSPR: 2.07 )
Ranked among companies with meaningful Current Ratio only.
NSPR' s Current Ratio Range Over the Past 10 Years
Min: 0.13  Med: 1.87 Max: 4.68
Current: 2.07
0.13
4.68
Quick Ratio 2.00
NSPR's Quick Ratio is ranked higher than
53% of the 327 Companies
in the Global Medical Devices industry.

( Industry Median: 1.82 vs. NSPR: 2.00 )
Ranked among companies with meaningful Quick Ratio only.
NSPR' s Quick Ratio Range Over the Past 10 Years
Min: 0.13  Med: 1.68 Max: 4.28
Current: 2
0.13
4.28
Days Inventory 109.48
NSPR's Days Inventory is ranked higher than
62% of the 290 Companies
in the Global Medical Devices industry.

( Industry Median: 134.83 vs. NSPR: 109.48 )
Ranked among companies with meaningful Days Inventory only.
NSPR' s Days Inventory Range Over the Past 10 Years
Min: 109.48  Med: 139.07 Max: 315.56
Current: 109.48
109.48
315.56
Days Sales Outstanding 119.04
NSPR's Days Sales Outstanding is ranked lower than
81% of the 277 Companies
in the Global Medical Devices industry.

( Industry Median: 66.89 vs. NSPR: 119.04 )
Ranked among companies with meaningful Days Sales Outstanding only.
NSPR' s Days Sales Outstanding Range Over the Past 10 Years
Min: 82.25  Med: 108.35 Max: 138.85
Current: 119.04
82.25
138.85

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -64.20
NSPR's 3-Year Average Share Buyback Ratio is ranked lower than
93% of the 209 Companies
in the Global Medical Devices industry.

( Industry Median: -3.90 vs. NSPR: -64.20 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
NSPR' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -141  Med: -85.15 Max: -34.4
Current: -64.2
-141
-34.4

Valuation & Return

vs
industry
vs
history
Price/Net Cash 0.96
NSPR's Price/Net Cash is ranked higher than
98% of the 98 Companies
in the Global Medical Devices industry.

( Industry Median: 16.84 vs. NSPR: 0.96 )
Ranked among companies with meaningful Price/Net Cash only.
NSPR' s Price/Net Cash Range Over the Past 10 Years
Min: 0.65  Med: 33.87 Max: 110.32
Current: 0.96
0.65
110.32
Price/Net Current Asset Value 0.76
NSPR's Price/Net Current Asset Value is ranked higher than
97% of the 196 Companies
in the Global Medical Devices industry.

( Industry Median: 6.51 vs. NSPR: 0.76 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
NSPR' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 0.51  Med: 20.07 Max: 80.94
Current: 0.76
0.51
80.94
Price/Tangible Book 0.65
NSPR's Price/Tangible Book is ranked higher than
96% of the 266 Companies
in the Global Medical Devices industry.

( Industry Median: 4.06 vs. NSPR: 0.65 )
Ranked among companies with meaningful Price/Tangible Book only.
NSPR' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.44  Med: 14.36 Max: 334.59
Current: 0.65
0.44
334.59
Price/Median PS Value 0.06
NSPR's Price/Median PS Value is ranked higher than
99% of the 231 Companies
in the Global Medical Devices industry.

( Industry Median: 1.02 vs. NSPR: 0.06 )
Ranked among companies with meaningful Price/Median PS Value only.
NSPR' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.04  Med: 0.97 Max: 8.7
Current: 0.06
0.04
8.7
Earnings Yield (Greenblatt) (%) 353.97
NSPR's Earnings Yield (Greenblatt) (%) is ranked higher than
99% of the 315 Companies
in the Global Medical Devices industry.

( Industry Median: 0.90 vs. NSPR: 353.97 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
NSPR' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 264.5  Med: 806.3 Max: 2327
Current: 353.97
264.5
2327

More Statistics

Revenue (TTM) (Mil) $2.09
EPS (TTM) $ -22.23
Beta-0.07
Short Percentage of Float27.04%
52-Week Range $1.41 - 23.94
Shares Outstanding (Mil)1.43

Analyst Estimate

Dec16 Dec17
Revenue (Mil $) 4 8
EPS ($) -0.73 -0.37
EPS w/o NRI ($) -0.73 -0.37
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for NSPR

Headlines

Articles On GuruFocus.com
Insiders Roundup: Sales on Facebook Mar 25 2016 
InspireMD Reports 4 Significant Insider Buys Apr 19 2013 

More From Other Websites
InspireMD Announces Change in Presentation Time at LD Micro Main Event Conference to Tuesday,... Dec 05 2016
InspireMD to Present at LD Micro Main Event on December 6 Nov 28 2016
INSPIREMD, INC. Financials Nov 19 2016
InspireMD, Inc. :NSPR-US: Earnings Analysis: Q3, 2016 By the Numbers : November 17, 2016 Nov 17 2016
INSPIREMD, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits Nov 15 2016
INSPIREMD, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Other Events,... Nov 14 2016
InspireMD Reports Financial Results for the Third Quarter Ended September 30, 2016 Nov 14 2016
INSPIREMD, INC. Files SEC form 10-Q, Quarterly Report Nov 14 2016
InspireMD Reports Financial Results for the Third Quarter Ended September 30, 2016 Nov 14 2016
InspireMD Announces CGuardTM Embolic Prevention System Commercialization Approval in Russia Nov 14 2016
InspireMD Announces CGuard(TM) Embolic Prevention System Commercialization Approval in Russia Nov 14 2016
InspireMD to Report Third Quarter Financial Results on Monday, November 14, 2016 Nov 07 2016
InspireMD to Report Third Quarter Financial Results on Monday, November 14, 2016 Nov 07 2016
INSPIREMD, INC. Files SEC form 8-K, Other Events Nov 04 2016
INSPIREMD, INC. Files SEC form 8-K, Regulation FD Disclosure, Other Events, Financial Statements and... Nov 02 2016
Ahead of The Presidential Election, These Stocks Are Hitting New Highs Nov 01 2016
Why InspireMD More Than Doubled Nov 01 2016
InspireMD CGuard™ Embolic Prevention System 12-Month Clinical Trial Data Further Validate... Nov 01 2016
InspireMD CGuard(TM) Embolic Prevention System 12-Month Clinical Trial Data Further Validate... Nov 01 2016
INSPIREMD, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Other Events,... Oct 27 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)